However, both early (when tumor size is around 10 mm3) and late (when tumor size is around 100–150 mm3) treatments with our anti-PVRIG mAb alone were effective against MC38 tumors in vivo, resulting in significant inhibition of tumor growth and prolonged survival of tumor-bearing mice. Here, PVRIG is linked to neoplasm.